A radioactive “bullet” cancer therapy could offer a new treatment for Hodgkin’s lymphoma patients after a successful experiment of the treatment.
The new CHT25 therapy uses an antibody that targets tumour cells linked to a radioactive particle, according to The Telegraph.
According to the results published in the journal Clinical Cancer Research, the treatment showed improvements in two thirds of the 15 patients involved with them either responding completely or partially to the drugs.
The UK’s Experimental Cancer Medicine Centre head of cancer research Prof Richard Begent who helped develop the treatment said that the initial results were very encouraging.
“There is an urgent need for new treatments for Hodgkin’s lymphoma and T-cell lymphoma because a number of patients develop drug resistance to the therapy options already out there,” Begent said.
The Phase II trial will be conducted at Cancer Research UK centres in London, Manchester and Southampton.